|
Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Kelun; Lilly/ImClone; Merck Sharp & Dohme; Novartis; Orion; Peptomyc; Pfizer; SERVIER; Spectrum Pharmaceuticals |
Research Funding - Bayer; Novartis |
|
|
Employment - MD Anderson Cancer Center |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Black Beret Life Sciences |
Research Funding - Phosplatin Therapeutics |
Travel, Accommodations, Expenses - Phosplatin Therapeutics |
|
|
|
Consulting or Advisory Role - Celgene; Halozyme; TYME |
Research Funding - ArQule (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health; Trovagene |
Stock and Other Ownership Interests - Guardant Health; Trovagene |
|
|
Employment - Guardant Health; Veracyte |
Leadership - Biolase; Guardant Health |
Stock and Other Ownership Interests - Biolase; Forward; Guardant Health |
Speakers' Bureau - Forward |
Research Funding - Guardant Health |
|
|
Stock and Other Ownership Interests - Sarepta Therapeutics |
Research Funding - Array BioPharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Taiho Pharmaceutical |
|
|
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen |
|
|
Honoraria - Dialectica; Sumitomo Group |
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; Genentech; Inflection Biosciences; Mersana; Origimed; Pieris Pharmaceuticals; Samsung Bioepis; Spectrum Pharmaceuticals; Xencor |
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim (I); Calithera Biosciences; Curis; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; eFFECTOR Therapeutics; Genentech; GlaxoSmithKline; Guardant Health (Inst); Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks |